See more : Gladstone Land Corporation (LANDM) Income Statement Analysis – Financial Results
Complete financial analysis of Nanjing Well Pharmaceutical Group Co.,Ltd. (603351.SS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Nanjing Well Pharmaceutical Group Co.,Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Chun Yu Works & Co., Ltd. (2012.TW) Income Statement Analysis – Financial Results
- Melhus Sparebank (MELG.OL) Income Statement Analysis – Financial Results
- Rio Tinto Group (RIO1.DE) Income Statement Analysis – Financial Results
- Fairfax Financial Holdings Limited (FRFGF) Income Statement Analysis – Financial Results
- Copland Road Capital Corporation (CRCC.CN) Income Statement Analysis – Financial Results
Nanjing Well Pharmaceutical Group Co.,Ltd. (603351.SS)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.well-js.com
About Nanjing Well Pharmaceutical Group Co.,Ltd.
Nanjing Well Pharmaceutical Group Co.,Ltd. focuses on the research and development, production, and sale of pharmaceutical auxiliary materials in China. Its pharmaceutical materials include excipients for injectables and non-injectables. The company also provides synthetic base oils, such as hydraulic fluids, lubricity additives for metals, metal quenching, base fluids and lubricity additives, synthetic base for compress lubricants, synthetic base oil for gear, base oil of chain lubricants, base stock of engine oil, base stock of heat transfer oil, and base oil of grease; and other products, including painting and coating, textile chemicals, field chemicals, and low foam metal cleaners. It also exports its products to Europe, the United States, Southeast Asia, and internationally. The company was formerly known as Nanjing Well Pharmaceutical Co.,Ltd. and changed its name to Nanjing Well Pharmaceutical Group Co.,Ltd. in April 2020. The company was founded in 2000 and is based in Nanjing, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.16B | 1.11B | 1.04B | 736.06M | 880.76M | 801.45M | 694.11M | 558.44M | 498.69M | 527.60M |
| Cost of Revenue | 842.97M | 807.96M | 747.92M | 484.23M | 577.53M | 552.14M | 451.62M | 333.81M | 338.67M | 392.71M |
| Gross Profit | 312.87M | 303.05M | 294.39M | 251.83M | 303.23M | 249.31M | 242.49M | 224.63M | 160.02M | 134.89M |
| Gross Profit Ratio | 27.07% | 27.28% | 28.24% | 34.21% | 34.43% | 31.11% | 34.94% | 40.22% | 32.09% | 25.57% |
| Research & Development | 55.64M | 53.87M | 41.46M | 36.59M | 32.91M | 24.70M | 23.28M | 17.57M | 15.17M | 15.73M |
| General & Administrative | 46.20M | 53.70M | 35.76M | 15.54M | 15.15M | 13.48M | 18.49M | 41.83M | 13.52M | 52.13M |
| Selling & Marketing | 6.20M | 12.18M | 14.13M | 10.47M | 39.99M | 31.56M | 28.31M | 20.61M | 19.35M | 19.47M |
| SG&A | 121.79M | 65.88M | 49.90M | 26.01M | 55.14M | 45.04M | 46.80M | 62.44M | 32.86M | 71.60M |
| Other Expenses | 13.66M | 62.27M | 74.11M | 74.81M | 58.13M | 3.41M | -222.26K | -7.84M | 484.55K | 399.82K |
| Operating Expenses | 191.09M | 182.02M | 165.47M | 137.40M | 146.19M | 115.40M | 111.39M | 121.75M | 78.80M | 73.72M |
| Cost & Expenses | 1.03B | 989.98M | 913.39M | 621.64M | 723.72M | 667.54M | 563.00M | 455.56M | 417.47M | 466.43M |
| Interest Income | 783.31K | 626.72K | 923.95K | 767.05K | 990.00K | 177.41K | 402.70K | 466.96K | 346.63K | 0.00 |
| Interest Expense | 15.52M | 11.18M | 7.04M | 5.00M | 4.91M | 5.33M | 3.20M | 5.14M | 8.06M | 8.11M |
| Depreciation & Amortization | 72.77M | 72.85M | 43.94M | 35.36M | 35.01M | 28.42M | 26.07M | 21.20M | 17.44M | 8.93M |
| EBITDA | 209.72M | 198.29M | 168.58M | 158.70M | 194.14M | 165.05M | 155.57M | 117.43M | 98.35M | 61.17M |
| EBITDA Ratio | 18.14% | 17.46% | 16.41% | 21.15% | 22.07% | 20.53% | 22.24% | 21.03% | 19.91% | 11.65% |
| Operating Income | 121.78M | 113.23M | 119.76M | 118.91M | 157.16M | 127.64M | 125.90M | 98.35M | 71.61M | 52.55M |
| Operating Income Ratio | 10.54% | 10.19% | 11.49% | 16.16% | 17.84% | 15.93% | 18.14% | 17.61% | 14.36% | 9.96% |
| Total Other Income/Expenses | -335.29K | -378.96K | -1.02M | -631.29K | -3.04M | 3.41M | -222.27K | -19.19M | 484.55K | 34.33K |
| Income Before Tax | 121.44M | 112.85M | 118.74M | 118.28M | 154.12M | 131.05M | 125.68M | 90.52M | 72.09M | 52.58M |
| Income Before Tax Ratio | 10.51% | 10.16% | 11.39% | 16.07% | 17.50% | 16.35% | 18.11% | 16.21% | 14.46% | 9.97% |
| Income Tax Expense | 12.33M | 18.42M | 18.59M | 17.83M | 26.01M | 19.24M | 18.24M | 16.81M | 11.36M | 7.71M |
| Net Income | 112.20M | 95.03M | 101.37M | 100.45M | 128.11M | 111.81M | 107.43M | 73.67M | 60.67M | 44.83M |
| Net Income Ratio | 9.71% | 8.55% | 9.73% | 13.65% | 14.55% | 13.95% | 15.48% | 13.19% | 12.17% | 8.50% |
| EPS | 0.83 | 0.72 | 0.78 | 0.77 | 0.98 | 1.14 | 1.10 | 0.75 | 1.07 | 0.79 |
| EPS Diluted | 0.83 | 0.72 | 0.78 | 0.77 | 0.98 | 1.14 | 1.10 | 0.75 | 1.07 | 0.79 |
| Weighted Avg Shares Out | 135.18M | 132.59M | 130.67M | 130.67M | 130.67M | 97.83M | 97.94M | 98.23M | 56.90M | 57.05M |
| Weighted Avg Shares Out (Dil) | 135.18M | 132.59M | 130.67M | 130.67M | 130.67M | 97.84M | 97.94M | 98.23M | 56.90M | 57.05M |
Source: https://incomestatements.info
Category: Stock Reports